Laura Brege
Director
Laura Brege serves as a member of our board of directors and is a Senior Advisor at BridgeBio Pharma (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to joining BridgeBio Pharma, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. From 2012 to 2015, Ms. Brege served as Chief Executive Officer and President of Nodality, Inc., a privately held biotechnology company focused in oncology and immunology. Previously, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc. (acquired by Amgen) from 2006 to 2011 including Executive Vice President and Chief Operating Officer. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Prior to Red Rock, she was Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege serves on the boards of Acadia Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., and HLS Therapeutics, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
